Home
Drugs
Tagrisso

Tagrisso

Drug

Drug Profile

Tagrisso is the brand name for osimertinib, a kinase inhibitor used in EGFR mutation-positive non-small cell lung cancer across adjuvant, unresectable stage III, first-line metastatic/locally advanced, and previously treated T790M-positive metastatic settings. U.S. labeling shows initial approval in 2015 with major indication updates through September 2024.

Drug Class: Kinase inhibitor (EGFR-targeted)
Approval Status: FDA approved (Initial U.S. Approval: 2015; major label updates through September 2024)
Mechanism of Action: EGFR-targeted kinase inhibition used for tumors with EGFR exon 19 deletion, exon 21 L858R, and T790M mutation contexts.

Brand Names

TAGRISSO

Indications

\Adjuvant therapy after tumor resection for adult NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation\
\Treatment of adult locally advanced unresectable stage III NSCLC without progression after platinum-based chemoradiation and with EGFR exon 19 deletion or exon 21 L858R mutation\
\First-line treatment of adult metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation\
\First-line combination with pemetrexed and platinum-based chemotherapy for locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation\
\Treatment of adult metastatic EGFR T790M mutation-positive NSCLC after progression on EGFR TKI therapy\

Related News

AstraZeneca Deepens China Push With COPD Drug License, Lung Cancer Deal and $15bn Investment

Aug 08, 2026

AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.

AstraZeneca Reports Strong Q1 2026 Results; Stock Sees Unusual Options Activity

Aug 03, 2026

AstraZeneca reported strong Q1 2026 results with 8% revenue growth and 12% operating profit growth, driven by its oncology portfolio and pipeline progress. The company also saw unusual options activity and maintained full-year guidance. Key oncology brands including Imfinzi and Enhertu showed double-digit growth.

AstraZeneca Q2 Profit Beats Forecasts, Sticks to 2030 Revenue Target Amid Pipeline Push

Jul 27, 2026

AstraZeneca Q2 core EPS of $2.63 beat consensus, driven by 15% oncology and 8% rare disease growth. The company maintained its 2030 $80 billion revenue target and has more than 20 Phase III readouts expected over the next 18 months.

Stage 4 Cancer Patients Share Survival Stories with Advanced Therapies

Jun 14, 2026

Patients with stage 4 lung, sarcoma, and gastro-oesophageal cancer describe their experiences with targeted therapies, chemotherapy, and immunotherapy, highlighting varying outcomes and financial challenges.

FDA Approves Monthly Dosing for Johnson & Johnson's Rybrevant Faspro in NSCLC

Mar 23, 2026

The FDA has approved a monthly subcutaneous dosing schedule for Johnson & Johnson's Rybrevant Faspro for EGFR-mutated NSCLC, based on PALOMA-2 trial data showing 82-87% response rates. The approval follows the drug's initial biweekly dosing approval in December 2025 and offers reduced administration time and reactions compared to intravenous delivery.

FDA Approves Monthly Dosing Schedule for Rybrevant Faspro in EGFR-Mutated Lung Cancer

Dec 18, 2025

The FDA approved a once-monthly dosing schedule for Rybrevant Faspro with Lazcluze for first-line treatment of EGFR-mutated advanced NSCLC, reducing clinic visits while maintaining safety and efficacy established with bi-weekly dosing.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT06306456	A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC	RECRUITING	PHASE1/PHASE2
NCT03969823	Whole Genomic Landscape of Advanced EGFR-mutant NSCLC	ACTIVE_NOT_RECRUITING	NA
NCT02824952	Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC	UNKNOWN	PHASE2